Holen Sie sich die Stockscreener-App
56.07
2.89%
-1.67
Schlusskurs vom Vortag:
$57.74
Offen:
$58.11
24-Stunden-Volumen:
408.51K
Relative Volume:
0.89
Marktkapitalisierung:
$3.45B
Einnahmen:
$112.53M
Nettoeinkommen (Verlust:
$-258.91M
KGV:
-12.95
EPS:
-4.33
Netto-Cashflow:
$-124.42M
1W Leistung:
-1.09%
1M Leistung:
-2.52%
6M Leistung:
+23.56%
1J Leistung:
+14.87%
1-Tages-Spanne:
$55.99
$58.45
1-Wochen-Bereich:
$55.99
$58.45
52-Wochen-Spanne:
$35.17
$68.58
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Firmenname
Rhythm Pharmaceuticals Inc
Sektor
Branche
Telefon
857-264-4280
Adresse
222 BERKELEY STREET, BOSTON, MA
Vergleichen Sie RYTM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
56.07 | 3.45B | 112.53M | -258.91M | -124.42M | -4.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-02 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-21 | Eingeleitet | Guggenheim | Buy |
| 2024-09-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-08-08 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Bestätigt | Needham | Buy |
| 2022-03-02 | Fortgesetzt | Stifel | Buy |
| 2022-02-17 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Fortgesetzt | Goldman | Neutral |
| 2021-08-04 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-01-08 | Eingeleitet | Goldman | Sell |
| 2019-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2019-07-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-03-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2018-06-25 | Bestätigt | Needham | Buy |
| 2018-06-15 | Bestätigt | Needham | Buy |
| 2017-10-30 | Eingeleitet | BofA/Merrill | Buy |
| 2017-10-30 | Eingeleitet | Needham | Buy |
Alle ansehen
Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten
Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight - GlobeNewswire Inc.
Cannon Financial Strategists Inc. Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Earns “Buy” Rating from Needham & Company LLC - Defense World
David P. Meeker Sells 9,896 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock - MarketBeat
Hunter C. Smith Sells 2,215 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Jennifer Kayden Lee Sells 2,035 Shares - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Christopher Paul German Sells 635 Shares - MarketBeat
Rhythm Pharmaceuticals (RYTM) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Rhythm Pharmaceuticals CAO Christopher German sells $36,334 in stock By Investing.com - Investing.com Australia
Needham & Company LLC Reiterates "Buy" Rating for Rhythm Pharmaceuticals (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals EVP sells stock worth $116,442 By Investing.com - Investing.com Australia
Rhythm Pharmaceuticals (RYTM) Expected to Announce Quarterly Earnings on Thursday - Defense World
Rhythm pharmaceuticals CTO Joseph Shulman sells $70,266 in stock - Investing.com India
Rhythm Pharmaceuticals CEO David Meeker sells $566,249 in stock - Investing.com India
Rhythm Pharmaceuticals CAO Christopher German sells $36,334 in stock - Investing.com India
Rhythm Pharmaceuticals CFO sells $126,742 in stock By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals CFO sells $126,742 in stock - Investing.com
Rhythm Pharmaceuticals' chief human resources officer sells $56,190 in stock - Investing.com
Rhythm Pharmaceuticals CEO David Meeker sells $566,249 in stock By Investing.com - Investing.com UK
Rhythm Pharmaceuticals Executives Sell Shares - TradingView
(RYTM) Technical Pivots with Risk Controls - Stock Traders Daily
7 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know - Benzinga
Buy Recommendation for Rhythm Pharmaceuticals: Promising Potential of Imcivree in Obesity Treatment - TipRanks
Investors in Rhythm Pharmaceuticals (NASDAQ:RYTM) have seen fantastic returns of 577% over the past three years - Simply Wall St
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Jennifer Kayden Lee Sells 1,815 Shares - MarketBeat
Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock? - MSN
Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 794 Shares of Stock - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Sells $246,773.99 in Stock - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Sells $74,532.96 in Stock - MarketBeat
Rhythm Pharmaceuticals Executives Conduct Stock Transactions - TradingView
abrdn plc Sells 32,287 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Needham & Company LLC Weighs in on RYTM FY2029 Earnings - MarketBeat
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on ... - The Bakersfield Californian
Rhythm Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire
Rare Disease Leader Rhythm Pharmaceuticals Sets Double Investor Events: Q4 Results & Major Healthcare Conference - StockTitan
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $68.09 Consensus Target Price from Analysts - Defense World
Research Analysts Set Expectations for RYTM FY2029 Earnings - Defense World
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Sells 1,678 Shares of Stock - MarketBeat
Jennifer Kayden Lee Sells 1,447 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock - MarketBeat
Joseph Shulman Sells 1,281 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock - MarketBeat
Long Term Trading Analysis for (RYTM) - Stock Traders Daily
KBC Group NV Buys 988 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CEO Sells 4,278 Shares of Stock - MarketBeat
JGP Global Gestao de Recursos Ltda. Has $301,000 Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
RYTMRhythm Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
RYTM (Rhythm Pharmaceuticals) Enterprise Value : $3,390.0 Mil (As of Feb. 05, 2025) - GuruFocus.com
Finanzdaten der Rhythm Pharmaceuticals Inc-Aktie (RYTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rhythm Pharmaceuticals Inc-Aktie (RYTM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Shulman Joseph | Chief Technical Officer |
Feb 19 '25 |
Sale |
57.22 |
1,228 |
70,266 |
8,509 |
| Meeker David P | President and CEO |
Feb 19 '25 |
Sale |
57.22 |
9,896 |
566,249 |
201,281 |
| Lee Jennifer Kayden | EVP, Head of North America |
Feb 19 '25 |
Sale |
57.22 |
2,035 |
116,443 |
5,858 |
| German Christopher Paul | Corporate Controller & CAO |
Feb 19 '25 |
Sale |
57.22 |
635 |
36,335 |
2,070 |
| Cramer Pamela J. | Chief Human Resources Officer |
Feb 19 '25 |
Sale |
57.22 |
982 |
56,190 |
19,209 |
| Smith Hunter C | Chief Financial Officer |
Feb 12 '25 |
Sale |
56.39 |
751 |
42,347 |
105,544 |
| Shulman Joseph | Chief Technical Officer |
Feb 12 '25 |
Sale |
56.40 |
469 |
26,452 |
5,612 |
| Lee Jennifer Kayden | EVP, Head of North America |
Feb 12 '25 |
Sale |
56.39 |
1,815 |
102,348 |
3,598 |
| Lee Jennifer Kayden | EVP, Head of North America |
Feb 13 '25 |
Sale |
58.00 |
1,205 |
69,890 |
2,393 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):